My Cart [ 0 ]
Home > Cell Biology > Stable Cell Lines > Xolair Biosimilar Stable Cell Line

Xolair Biosimilar Stable Cell Line

Omalizumab, Anti-IgE Humanized Monoclonal Antibody

Catalog No. Product Name Size List Price (US$) Quantity
C020 Xolair Biosimilar Stable Cell Line 1 package Request
Description

Omalizumab (trade name Xolair, Roche/Genentech and Novartis) is a humanized antibody used to reduce sensitivity to inhaled or ingested allergens, especially in the control of moderate to severe allergic asthma which does not respond to high doses of corticosteroids.

Immunoglobulin E (IgE) found in mammals only exists as monomers consisting of two heavy chains (ε chain) and two light chains, with the ε chain containing 4 Ig-like constant domains (Cε1-Cε4). In addition to immunity to parasites, IgE plays an essential role in type I hypersensitivity, which manifests various allergic diseases, and allergic conditions, such as anaphylactic reactions to certain drugs, bee stings, and antigen preparations used in specific desensitization immunotherapy.

Omalizumab specifically binds to free IgE in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, omalizumab does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.

C020: Xolair Biosimilar Stable Cell Line (CHO)

The yield of Xolair biosimilar from the CHO stable cell line was above 3.0 g/L in a 3 liter manufacturing.

The Xolair biosimilar stable cell line alone can be transfered alone or together with the technology of process development and/or antibody purification.

Related Links

See our Privacy Policy